Roche Licenses Sequencing Technology
Dr. Lindsay told the Phoenix Business Journal that Roche licensed five patent applications. In August, Dr. Lindsay received a four-year, $4.1 million grant from the NIH’s National Human Genome Research Institute to develop a DNA sequencing system using recognition tunneling, which can provide an electronic signature for each individual DNA base and 5-methyl C.
Branford, CT and Tempe, AZ 10/11/11—Roche has agreed to license several technologies developed by Dr. Stuart Lindsay at the Biodesign Institute at Arizona State University and Dr. Colin Nuckolls of Columbia University Nanoscience Center. The technologies include specialized approaches for DNA base sensing and reading and will be used in Roche’s development of a single-molecule, nanopore DNA sequencer. “This will complement the DNA Transistor technology from our previously announced collaboration with IBM very well to form the core of a superior platform for extremely fast, very low-cost genome sequencing,” commented Thomas Schinecker, president of Roche 454 Life Sciences. Both this technology and IBM’s technology are related to semiconductor-based nanopores, according to Roche. Dr. Lindsay stated that the technology does not require the use of chemical reagents.
